Condition
Advanced Esophageal Squamous Cell Cancer
Total Trials
4
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 2 (4)
Trial Status
Unknown4
Clinical Trials (4)
Showing 4 of 4 trials
NCT05323890Phase 2UnknownPrimary
Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.
NCT04797507Phase 2Unknown
SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer
NCT04437212Phase 2UnknownPrimary
Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer
NCT03732508Phase 2UnknownPrimary
SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer
Showing all 4 trials